HeartBeam announces availability of shareholder letter
HeartBeam posted a shareholder letter outlining a strategic pivot toward heart attack detection using its 3D ECG technology. Plan drops a large commercial build-out for its FDA-cleared arrhythmia product, keeping only limited commercialization to support select customers. Resources shift to MI detection clinical valida